List of monoclonal antibodies

This MedLibrary.org supplementary page on List of monoclonal antibodies is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Related Sponsors

BM Pharmacy Generic pharmaceuticals at unbeatable prices. Insomnia, men's health, hair health, pain control. bmpharmacy.com
Online Pharmacy Carisoprodol, tadalafil, sildenafil, vardenafil and more... xlpharmacy.com
MedBasket.com Discreet. Inexpensive. Fast shipping. Great selection. What more can we say? medbasket.com
Frugalmed 2000 reasons to shop with us first. frugalmed.com
Ads by Tiva

This is a list of therapeutic monoclonal antibodies, antibodies which are clones of a single parent cell. When used as medications, the generic names end in -mab (see "Nomenclature of monoclonal antibodies").

Name Target Source Notes
3F8 tu(m) o binds to GD2, used in treatment of neuroblastoma
Abagovomab go(v) o
Abciximab ci(r) xi
Adalimumab li(m) u
Adecatumumab tu(m) u
Afutuzumab tu(m) zu
Alemtuzumab tu(m) zu
Altumomab tu(m) o
Afelimomab li(m) o
Anatumomab mafenatox tu(m) o
Anrukizumab ki(n) zu
Apolizumab li(m) zu
Arcitumomab tu(m) o
Aselizumab li(m) zu
Atlizumab li(m) zu
Atorolimumab li(m) u
Bapineuzumab neu(r) zu
Basiliximab li(m) xi
Bavituximab tu(m) xi
Bectumomab tu(m) o
Belimumab li(m) u
Bertilimumab li(m) u
Besilesomab le(s) o
Bevacizumab ci(r) zu
Biciromab brallobarbital ci(r) o
Bivatuzumab mertansine tu(m) zu
Campath - Redirects to alemtuzumab tu(m) zu
Canakinumab ki(n) u
Cantuzumab mertansine tu(m) zu
Capromab pr(o) o
Catumaxomab tu(m) axo
Cedelizumab li(m) zu
Certolizumab pegol li(m) zu
Cetuximab tu(m) xi
Citatuzumab bogatox tu(m) zu
Cixutumumab tu(m) u
Clenoliximab li(m) xi
Conatumumab tu(m) u
Dacetuzumab tu(m) zu
Dacliximab - Redirects to daclizumab li(m) zu
Daclizumab li(m) zu
Denosumab o(s) u
Detumomab tu(m) o
Dorlimomab aritox li(m) o
Dorlixizumab li(m) xizu
Ecromeximab me(l) xi
Eculizumab li(m) zu
Edobacomab ba(c) o
Edrecolomab co(l) o
Efalizumab li(m) zu blocks T-cell migration
Efungumab fu(ng) u
Elsilimomab li(m) o
Enlimomab pegol li(m) o
Epitumomab cituxetan tu(m) o
Epratuzumab tu(m) zu
Erlizumab li(m) zu
Ertumaxomab tu(m) axo
Etanercept  ?  ?
Etaracizumab ci(r) zu
Etaratuzumab tu(m) zu
Exbivirumab vi(r) u
Efalizumab li(m) zu
Fanolesomab le(s) o
Faralimomab li(m) o
Felvizumab vi(r) zu
Fontolizumab li(m) zu
Galiximab li(m) xi
Gantenerumab ne(r) u
Gavilimomab li(m) o
Gemtuzumab ozogamicin tu(m) zu
Golimumab li(m) u
Gomiliximab li(m) xi
Ibalizumab li(m) zu
Ibritumomab tiuxetan tu(m) o
Igovomab go(v) o
Imciromab ci(r) o
Infliximab li(m) xi
Inolimomab li(m) o
Inotuzumab ozogamicin tu(m) zu
Ipilimumab li(m) u
Iratumumab tu(m) u
Ixutumumab tu(m) u
Keliximab li(m) xi
Labetuzumab tu(m) zu
Lemalesomab le(s) o
Lebrilizumab li(m) zu
Lerdelimumab li(m) u
Lexatumumab tu(m) u
Lexitumumab tu(m) u
Libivirumab vi(r) u
Lintuzumab tu(m) zu
Lucatumumab tu(m) u
Lumiliximab li(m) xi
Mapatumumab tu(m) u
Maslimomab li(m) o
Matuzumab tu(m) zu
Mepolizumab li(m) zu
Metelimumab li(m) u
Milatuzumab tu(m) zu
Minretumomab tu(m) o
Mitumomab tu(m) o
Morolimumab li(m) u
Motavizumab vi(r) zu
Muromonab-CD3 monoclonal antibody  ? o
Nacolomab tafenatox co(l) o
Naptumomab estafenatox tu(m) o
Natalizumab li(m) zu
Nebacumab ba(c) u
Nerelimomab li(m) o
Nimotuzumab tu(m) zu
Nofetumomab merpentan tu(m) o
Ocrelizumab li(m) zu
Odulimomab li(m) o
Ofatumumab tu(m) u
Omalizumab li(m) zu
Oregovomab go(v) o
Otelixizumab li(m) xizu
Pagibaximab ba(c) xi
Palivizumab vi(r) zu
Panitumumab tu(m) u
Pascolizumab li(m) zu
Pemtumomab tu(m) o
Pertuzumab tu(m) zu
Pexelizumab li(m) zu
Pintumomab tu(m) o
Priliximab li(m) xi
Pritumumab tu(m) u
PRO 140 vi(r) zu
Rafivirumab vi(r) u
Ramucirumab ci(r) u
Ranibizumab  ? zu
Raxibacumab ba(c) u
Regavirumab vi(r) u
Reslizumab li(m) zu
Rituximab tu(m) xi
Robatumumab tu(m) u
Rovelizumab li(m) zu
Ruplizumab li(m) zu
Satumomab tu(m) o
Sevirumab vi(r) u
Sibrotuzumab tu(m) zu
Siplizumab li(m) zu
Sontuzumab tu(m) zu
Stamulumab mu(l) u
Stolanezumab ne(r) zu
Sulesomab le(s) o
Tacatuzumab tetraxetan tu(m) zu
Tadocizumab ci(r) zu
Talizumab li(m) zu
Tanezumab ne(r) zu
Taplitumomab paptox tu(m) o
Tefibazumab ba(c) zu
Telimomab aritox li(m) o
Tenatumomab tu(m) o
Teneliximab li(m) xi
Teplizumab li(m) zu
Ticilimumab - Redirects to tremelimumab li(m) u
Tigatuzumab tu(m) zu
Tocilizumab li(m) zu
Toralizumab li(m) zu
Tositumomab tu(m) o
Trastuzumab tu(m) zu
Tremelimumab li(m) u
Tucotuzumab celmoleukin tu(m) zu
Tuvirumab vi(r) u
Urtoxazumab tox(a) zu
Ustekinumab ki(n) u
Vapaliximab li(m) xi
Vedolizumab tu(m) zu
Veltuzumab tu(m) zu
Vepalimomab li(m) o
Visilizumab li(m) zu
Volociximab ci(r) xi
Votumumab tu(m) u
Zalutumumab tu(m) u
Zanolimumab li(m) u
Ziralimumab li(m) u
Zolimomab aritox li(m) o

Wikipedia content modification information:

  • This page was last modified on 12 October 2008, at 14:51.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "List of monoclonal antibodies".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.